This year’s European Lung Cancer Congress (ELCC) was a great opportunity to get a complete update and overview of new trends, opinions and innovations in lung malignancies as far as immuno-therapy, targeted therapy and biomarker research are concerned.
The ELCC organized several yes/no discussions, numerous educational sessions, chose interesting posters and abstracts for oral presentation. New data were limited since the annual ASCO meeting (American Association of Clinical Oncology) is not even one month later beginning of June and thus extremely close to the annual ELCC meeting. Usually these meetings are 2 months apart.
MedInContext really enjoyed this high quality and high impact European Congress and listened and talked to lung experts about the broad spectrum of data collected over the past years. So much has happened in lung cancer especially non small cell lung cancer (NSCLC). Sometimes it is necessary to take a step back and to look at everything from a distance to understand the direction for next steps.
The topics that we paid particular attention to included EGFR mutation positive NSCLC and resistance mechanisms, ALK-rearranged NSCLC, immuno therapy for NSCLC and biomarkers in NSCLC. In addition, genetic profiling of lung cancer earned tremendous attention through its recognition as a topic for the keynote lecture. Further topics discussed at the ELCC included new techniques in surgery and radiotherapy and novel targets of current or future clinical importance depending if new molecules are in the pipeline or if already available drugs are able to affect these as well.